IFIH1 and myositis disease: Recent studies have highlighted the importance of evaluating myositis-specific autoantibodies, in particular, the anti-melanoma differentiation-associated gene 5 (MDA5) and anti-aminoacyl tRNA synthetase (ARS) antibodies, in order to evaluate clinical phenotypes and treatment choices.